Effects of Human Urinary Kallidinogenase on Early Improvement and Functional Outcomes in Acute Ischemic Stroke (TK-SPEED)

This is a multicentre, randomized, open label, blinded-endpoint trial that aims to investigate the effects of Human Urinary Kallidinogenase treatment on neurological outcomes, early cerebral perfusion in patients with acute anterior circulation ischemic stroke. Patients in intervention group will be given 0.15 peptide nucleic acids (PNA) Human Urinary Kallidinogenase concentrated solution for intravenous injection once a day for 10 days continuously, and those in the control group will be given conventional therapy. Both groups of patients will be on standard stroke care. In this study, patients who were eligible to the inclusion criteria and ineligible to the exclusion criteria will be randomly assigned into two groups by a 1:1 ratio after the informed consent form (ICF) was received. The total sample size will be 540. All patients will be followed up for 90 days. The primary outcome is the proportion of modified Rankin Scale 0-2. Besides, the investigators aimed to use computed tomography perfusion (CTP) evaluate the differences of ischemic penumbra volume and regional cerebral blood flow (rCBF) before and after treatment between intervention group and control group.

Furthermore, this study adopts adaptive design, prospectively stating interim analyses with specified stopping rules, which allow for the possibility of the study to terminate early based on either determination of study success or of the futility to continue further enrollment.

Inclusion criteria

• 18 to 80 years of age;
• Diagnosis of anterior circulation acute ischemic stroke;
• Within 48 hours of symptoms onset;
• modified Rankin Scale (mRS) score≤1 before this event;
• 5≤NIHSS≤20 at screening;
• The availability of informed consent.

Exclusion criteria

• Patients who have already or are going to receive intravenous thrombolytic/mechanical thrombectomy therapy after onset;
• Patients with severe consciousness disorder, NIHSS 1a consciousness level score≥2;
• Patients with limited limb mobility such as fractures and claudication upon admission;
• Patients who have already or are going to receive Edaravone injection, Edaravone and DeKanol concentrated solution for injection, Butylphthalide and sodium chloride injection or Butylphthalide soft capsules after onset;
• Hypotensive (systolic blood pressure <90 mmHg or diastolic blood pressure<60 mmHg) on admission;
• History of severe drug or food allergy, allergy or intolerance to Human Urinary Kallidinogenase;
• Patients who have been on angiotensin-converting enzyme inhibitor (ACEI) drugs and within 5 half-lives (according to the specific drug instructions) before initiate Human Urinary Kallidinogenase treatment;
• Pregnancy, lactation, or planned pregnancy within 90 days;
• Patients with severe renal failure or impairment (eGFR<30ml/min/1.73m2) at screening;
• Severe hepatic dysfunction, elevation of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) (more than 2.5 times of upper limit of normal value), other liver diseases such as acute and chronic hepatitis, cirrhosis, etc;
• Patients with heart failure (NYHA class III or IV), unstable angina pectoris, acute myocardial infarction, severe arrhythmia, and degree II and III cardiac conduction obstruction within 6 months prior to randomization;
• Heavy drinking in the three months before screening, drinking≥5 standard drinks per day (1 standard drink is equivalent to120ml wine, 360ml beer or 45ml liquor);
• Drug Abuse or addiction in the past year;
• Patients with a malignant tumor, severe systemic diseases, or estimated survival time <90 days;
• Patients with severe mental disorders or dementia unable to complete the informed consent and follow-up;
• Have participated in another interventional clinical study within 30 days before randomization or are participating in another interventional clinical study;
• Other cases unsuitable for this clinical study assessed by researcher.